SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)

被引：0

作者：

Lang, I. ^{[1
]}

Inbar, M. ^{[2
]}

Greil, R. ^{[3
]}

Kahan, Z. ^{[4
]}

Beslija, S. ^{[5
]}

Steger, G. G. ^{[6
]}

Stemmer, S. M. ^{[7
]}

Zvribule, Z. ^{[8
]}

Kaufman, B. ^{[9
]}

Zielinski, C. ^{[10
,11
]}

机构：

[1] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary

[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel

[3] Med Univ Salzburg, Dept Med, Salzburg, Austria

[4] Univ Med Sch Szeged, Szeged, Hungary

[5] Inst Oncol, Sarajevo, Bosnia & Herceg

[6] Med Univ Vienna, Med & Canc Ctr, Vienna, Austria

[7] Davidoff Ctr, Petah Tiqwa, Israel

[8] Riga Eastern Hosp, Latvian Ctr Oncol, Riga, Latvia

[9] Chaim Sheba Med Ctr, Div Oncol, Ramat Gan, Israel

[10] Univ Hosp, Dept Med 1, Vienna, Austria

[11] Ctr Canc, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：98 / 98

页数：1

共 50 条

[31] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer [J].

Tiainen, Leena ;

Tanner, Minna ;

Lahdenpera, Outi ;

Vihinen, Pia ;

Jukkola, Arja ;

Karihtala, Peeter ;

Paunu, Niina ;

Huttunen, Teppo ;

Kellokumpu-Lehtinen, Pirkko-Liisa .

ANTICANCER RESEARCH, 2016, 36 (12) :6431-6438

[32] Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120) [J].

Ito, Y. ;

Aogi, K. ;

Masuda, N. ;

Ohno, S. ;

Oda, T. ;

Iwata, H. ;

Kashiwaba, M. ;

Fujiwara, Y. ;

Kamigaki, S. ;

Ueno, T. ;

Takashima, S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[33] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC) [J].

Gluck, S. ;

Lobo, C. ;

Reis, I. ;

Lopes, G. ;

Carmody, C. ;

Tukia, K. ;

Hurley, J. ;

Seo, P. ;

Silva, O. ;

Slingerland, J. ;

Welsh, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[34] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer [J].

Katherine F. Croom ;

Sohita Dhillon .

Drugs, 2011, 71 :2213-2229

[35] Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): A singlecenter phase II study [J].

Inno, A. ;

Strippoli, A. ;

Nazzicone, G. ;

Quaranta, A. ;

Di Salvatore, M. ;

Galiano, A. ;

Bagala, C. ;

Basso, M. ;

Pozzo, C. ;

Cassano, A. ;

Astone, A. ;

Barone, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[36] First results of AVEREL, a randomized phase Ill trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) plus docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) [J].

Gianni, L. ;

Romieu, G. ;

Lichinitser, M. ;

Serrano, S. ;

Mansutti, M. ;

Pivot, X. ;

Smirnova, I. ;

Moliterni, A. ;

Andre, F. ;

Chan, A. ;

Lipatov, O. ;

Chan, S. ;

Wardley, A. ;

Greil, R. ;

Provencher, L. ;

Moore, N. ;

Prot, S. ;

Semiglazov, V. .

CANCER RESEARCH, 2011, 71

[37] First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study [J].

Andreis, D. ;

Scandurra, G. ;

Santini, D. ;

Gucciardino, C. ;

La Verde, N. M. ;

Girelli, S. ;

Alabiso, I. ;

Saetta, A. ;

Atzori, F. ;

Collova, E. ;

Ferzi, A. ;

Gori, S. ;

Lipari, H. ;

Saggia, C. ;

Marcon, I. ;

Generali, D. G. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[38] First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) In Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study [J].

Foerster, F. ;

Aktas, B. ;

Geberth, M. ;

Tschechne, B. ;

Schneeweiss, A. ;

Salat, C. ;

Tesch, H. ;

Welslau, M. ;

Schmidt, M. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :S351-S352

[39] Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC) [J].

Borson, R. ;

Harker, W. G. ;

Reeves, J. E. ;

Drosick, D. ;

Beck, J. T. ;

Hager, S. J. ;

Horvath, W. L. ;

Bromund, J. ;

Zeigler, H. ;

Tai, D. ;

Yardley, D. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[40] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study [J].

Dieras, Veronique ;

Pop, Simona ;

Berger, Frederique ;

Dujaric, Marie-Eglantine ;

Beuzeboc, Philippe ;

Escalup, Laurence ;

Bidard, Francois Clement ;

Cottu, Paul Henri ;

Le Tourneau, Christophe ;

Piperno-Neumann, Sophie ;

Laurence, Valerie ;

Robain, Mathieu ;

Asselain, Bernard ;

Pierga, Jean-Yves .

ANTICANCER RESEARCH, 2017, 37 (03) :1403-1407

← 1 2 3 4 5 →